Targeting p73 - a Potential Approach in Cancer Treatment

Current Pharmaceutical Design

Volumn 17, Issue 6, 2011, Pages 591-602

  Slade, Neda ^a   Horvat, Andela ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Apoptosis; Cancer; Cancer therapy; Chemosensitivity; p73

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; APOPTOSIS STIMULATING PROTEIN OF P53; AURORA A KINASE; AURORA KINASE INHIBITOR; BLEOMYCIN; CAMPTOTHECIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DNA; DOXORUBICIN; ELLIPTICINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MICRORNA; MITOXANTRONE; MLN 8237; NSC 176327; NUTLIN 3; PACLITAXEL; PROTEIN P53; PROTEIN P63; PROTEIN P73; PRYVINIUM; RAPAMYCIN; REACTIVATION OF TRANSCRIPTIONAL REPORTER ACTIVITY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER GENE THERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOSENSITIVITY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

EID: 79953650802     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795222621     Document Type: Review

References (149)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-6.
2. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
3. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27- 29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
4. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
5. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99-103.
6. Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-91.
7. Wilhelm MT, Rufini A, Wetzel MK, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010; 24: 549-60.
8. Scoumanne A, Harms KL, Chen X. Structural basis for gene activation by p53 family members. Cancer Biol Ther 2005; 4: 1178-85.
9. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-37.
10. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004: 2: 371-86.
11. Slade N, Zoristreetč /streetA, Horvat A. The p53/p63/p73 family of proteins - the focus on isoforms and mutants in cancer. Period Biol 2011; in press.
12. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 636-41.
13. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21: 182-91.
14. Liu G, Nozell S, Xiao H, Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004; 24: 487-501.
15. Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63: 2351-7.
16. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113: 1661-70.
17. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, a dominantnegative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196: 765-80.
18. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289: 304-6.
19. Fontemaggi G, Kela I, Amariglio N, et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277: 43359-68.
20. Kartasheva NN, Lenz-Bauer C, Hartmann O, Schafer H, Eilers M, Dobbelstein M. DeltaNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 2003; 22: 8246-54.
21. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 1999: 274: 18709-14.
22. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438-49.
23. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47-54.
24. Vikhanskaya F, D'Incalci M, Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res 2000; 28: 513-9.
25. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-87.
26. Strano S, Munarriz E, Rossi M, et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275: 29503-12.
27. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. Transactivation- deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62: 3598-602.
28. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
29. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-80.
30. Slade N, Zaika AI, Erster S, Moll UM. DeltaNp73 stabilizes TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ 2004; 11: 357-60.
31. Cui R, Nguyen TT, Taube JH, Stratton SA, Feuerman MH, Barton MC. Family members p53 and p73 act together in chromatin modification and direct repression of alpha-fetoprotein transcription. J Biol Chem 2005; 280: 39152-60.
32. Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI. Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther 2010; 9: 693-705.
33. Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002; 22: 2575-85.
34. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 2002; 21: 4715-27.
35. Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8: 1213-23.
36. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103: 11003-8.
37. Chen X, Zheng Y, Zhu J, Jiang J, Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 2001; 20: 769-74.
38. Wang J, Liu YX, Hande MP, Wong AC, Jin YJ, Yin Y. TAp73 is a downstream target of p53 in controlling the cellular defense against stress. J Biol Chem 2007; 282: 29152-62.
39. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9: 897-903.
40. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-73.
41. Beitzinger M, Hofmann L, Oswald C, et al. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 2008; 27: 792-803.
42. Vilgelm A, El-Rifai W and Zaika A, Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 11(4-5): 152-63, 2008.
43. Concin N, Becker K, Slade N, et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64: 2449-60.
44. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 2002; 8: 165-70.
45. Becker K, Pancoska P, Concin N, et al. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol 2006; 29: 889-902.
46. Bozzetti C, Nizzoli R, Musolino A, et al. p73 and p53 pathway in human breast cancers. J Clin Oncol 2007; 25: 1451-3.
47. Casciano I, Mazzocco K, Boni L, et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9: 246-51.
48. Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24: 805-15.
49. Frasca F, Vella V, Aloisi A, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003; 63: 5829-37.
50. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol 2005; 58: 1175-9.
51. Tuve S, Wagner SN, Schittek B, Pützer BM. Alterations of DeltaTA- p73 splice transcripts during melanoma development and progression. Int J Cancer 2004; 108: 162-6.
52. Uramoto H, Sugio K, Oyama T, et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004; 10: 6905-11.
53. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K. Expression of the p53 family in lung cancer. Anticancer Res 2006; 26: 1785-90.
54. Wager M, Guilhot J, Blanc JL, et al. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 2006; 95: 1062-9.
55. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59: 3257-63.
56. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11: 8372-83.
57. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10: 626-33.
58. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 2006; 12: 3922-7.
59. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399: 809-13.
60. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002; 9: 175-86.
61. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-9.
62. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-7.
63. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73- dependent apoptosis. Cancer Cell 2003; 3: 387-402.
64. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-10.
65. Chung J, Irwin MS. Targeting the p53-family in cancer and chemosensitivity: triple threat. Curr Drug Targets 2010; 11: 667-81.
66. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 2009; 15: 6495-502.
67. Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedstrom E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle 2010; 9: 720-8.
68. Alsafadi S, Tourpin S, Andre F, Vassal G, Ahomadegbe JC. p53 family: at the crossroads in cancer therapy. Curr Med Chem 2009; 16: 4328-44.
69. Ding Y, Inoue T, Kamiyama J, et al. Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. DNA Res 1999; 6: 347-51.
70. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1- induced apoptosis. Nat Genet 2000; 26: 464-9.
71. Marabese M, Vikhanskaya F, Rainelli C, Sakai T, Broggini M. DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res 2003; 31: 6624-32.
72. Wu S, Murai S, Kataoka K, Miyagishi M. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem Biophys Res Commun 2008; 365: 75-81.
73. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004; 18: 3041-54.
74. Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001; 276: 11310-6.
75. Flinterman M, Guelen L, Ezzati-Nik S, et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 2005; 280: 5945-59.
76. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res 1999; 59: 3352-6.
77. Pluta A, Nyman U, Joseph B, Robak T, Zhivotovsky B, Smolewski P. The role of p73 in hematological malignancies. Leukemia 2006; 20: 757-66.
78. Siu LL, Chan JK, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 2002; 160: 59-66.
79. Casciano I, Banelli B, Croce M, et al. Role of methylation in the control of DeltaNp73 expression in neuroblastoma. Cell Death Differ 2002; 9: 343-5.
80. Daskalos A, Logotheti S, Markopoulou S, et al. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett 2011; 300: 79-86.
81. Tsai KK, Yuan ZM. c-Abl stabilizes p73 by a phosphorylationaugmented interaction. Cancer Res 2003; 63: 3418-24.
82. Wang X, Zeng L, Wang J, et al. A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 2010; 18: 5-15.
83. Gonzalez S, Prives C, Cordon-Cardo C. p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol 2003; 23: 8161-71.
84. Furuya K, Ozaki T, Hanamoto T, et al. Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin-induced apoptosis. J Biol Chem 2007; 282: 18365-78.
85. Ren J, Datta R, Shioya H, et al. p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem 2002; 277: 33758-65.
86. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002; 21: 974-9.
87. Bernassola F, Salomoni P, Oberst A, et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 1545-57.
88. Zhao LY, Liu Y, Bertos NR, Yang XJ, Liao D. PCAF is a coactivator for p73-mediated transactivation. Oncogene 2003; 22: 8316-29.
89. Strano S, Munarriz E, Rossi M, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276: 15164-73.
90. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14: 743-51.
91. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 2008; 29: 350-61.
92. Danovi SA, Rossi M, Gudmundsdottir K, Yuan M, Melino G, Basu S. Yes-associated protein (YAP) is a critical mediator of c-Jundependent apoptosis. Cell Death Differ 2008; 15: 217-9.
93. Jones EV, Dickman MJ, Whitmarsh AJ. Regulation of p73- mediated apoptosis by c-Jun N-terminal kinase. Biochem J 2007; 405: 617-23.
94. Mantovani F, Piazza S, Gostissa M, et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 2004; 14: 625-36.
95. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-94.
96. Bergamaschi D, Samuels Y, O'Neil NJ, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162-7.
97. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004; 24: 1341-50.
98. Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 2001; 276: 14514-23.
99. Gaiddon C, Lokshin M, Gross I, et al. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 2003; 278: 27421-31.
100. Koida N, Ozaki T, Yamamoto H, et al. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 2008; 283: 8555-63.
101. Paliwal P, Radha V, Swarup G. Regulation of p73 by Hck through kinase-dependent and independent mechanisms. BMC Mol Biol 2007; 8: 45.
102. Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 2004; 101: 4401-6.
103. Hanamoto T, Ozaki T, Furuya K, et al. Identification of protein kinase A catalytic subunit beta as a novel binding partner of p73 and regulation of p73 function. J Biol Chem 2005; 280: 16665-75.
104. Lee AF, Ho DK, Zanassi P, Walsh GS, Kaplan DR, Miller FD. Evidence that DeltaNp73 promotes neuronal survival by p53- dependent and p53-independent mechanisms. J Neurosci 2004; 24: 9174-84.
105. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18(27): 3923-9.
106. Dobbelstein M, Wienzek S, Konig C, Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999: 18: 2101-6.
107. Ongkeko WM, Wang XQ, Siu WY, et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 1999; 9: 829-32.
108. Zeng X, Chen L, Jost CA, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19: 3257-66.
109. Gu J, Nie L, Kawai H, Yuan ZM. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res 2001; 61: 6703-7.
110. Rossi M, De Laurenzi V, Munarriz E, et al. The ubiquitin-protein ligase Itch regulates p73 stability. Embo J 2005; 24: 836-48.
111. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ 2004; 11: 685-7.
112. Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 2009; 28: 3157-66.
113. Hosoda M, Ozaki T, Miyazaki K, et al. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 2005; 24: 7156-69.
114. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin- independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19: 316-21.
115. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275: 36316-23.
116. Lin KW, Nam SY, Toh WH, Dulloo I, Sabapathy K. Multiple stress signals induce p73beta accumulation. Neoplasia 2004; 6: 546-57.
117. Müller M, Schilling T, Sayan AE, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-77.
118. Thottassery JV, Westbrook L, Someya H, Parker WB. c-Ablindependent p73 stabilization during gemcitabine- or 4'-thio-beta- D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther 2006; 5: 400-10.
119. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Benard J, Ahomadegbe JC. p73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116: 860-9.
120. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-4.
121. Meier M, den Boer ML, Meijerink JP, et al. Differential expression of p73 isoforms in relation to drug resistance in childhood Tlineage acute lymphoblastic leukaemia. Leukemia 2006; 20: 1377-84.
122. Johnson RA, Shepard EM, Scotto KW. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 2005; 280: 13213-9.
123. Vilgelm A, Wei JX, Piazuelo MB, et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 2008; 27: 2170-6.
124. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-15.
125. Machado-Silva A, Perrier S, Bourdon JC. p53 family members in cancer diagnosis and treatment. Semin Cancer Biol 2010; 20: 57-62.
126. Di Agostino S, Cortese G, Monti O, et al. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle 2008; 7: 3440-7.
127. Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Smallmolecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-7.
128. Guida E, Bisso A, Fenollar-Ferrer C, et al. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res 2008; 68: 6550-8.
129. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007; 117: 1008-18.
130. Bell HS, Ryan KM. iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res 2008; 68: 4959-62.
131. Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 2008; 7: 2039-46.
132. Lau LM, Wolter JK, Lau JT, et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009; 28: 2024-33.
133. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008; 28: 5951-64.
134. Wong SW, Tiong KH, Kong WY, et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through upregulation of p73. Breast Cancer Res Treat. 2010, E-pub ahead of print
135. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
136. Sun Q, Ming L, Thomas SM, et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009; 28: 2348-57.
137. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55-62.
138. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008; 68: 8998-9004.
139. Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73- p53AIP1 apoptotic pathway in leukemia cells. Blood 2004; 104: 519-25.
140. Hansen TM, Rossi M, Roperch JP, et al. Itch inhibition regulates chemosensitivity in vitro. Biochem Biophys Res Commun 2007; 361: 33-6.
141. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxideinduced apoptosis. Blood 2006; 107: 4549-53.
142. Sayan AE, Sayan BS, Gogvadze V, et al. p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAILinduced apoptosis. Oncogene 2008; 27: 4363-72.
143. Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 2003; 22: 8394-402.
144. Sasaki Y, Morimoto I, Ishida S, Yamashita T, Imai K, Tokino T. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of cancer. Gene Therapy 2001; 8:1401-8.
145. Rödicker F, Pützer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res 2003; 63: 2737-41.
146. Tuve S, Racek T, Niemetz A, Schultz J, Soengas MS, Pützer BM. Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas. Apoptosis 2006; 11: 235-43.
147. Das S, Nama S, Antony S, Somasundaram K. p73 beta-expressing recombinant adenovirus: a potential anticancer agent. Cancer Gene Ther 2005; 12: 417-26.
148. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007; 12: 414-8.
149. Sampath D, Calin GA, Puduvalli VK, et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009; 113: 3744-53.